March 17, 2023 01:51 PM EDTUpdated 05:38 PM
Pharma
FDA+

No­var­tis' Tafin­lar/Mekin­ist com­bo scores new in­di­ca­tion in pe­di­atric brain can­cer

Katherine Lewin

News Reporter

No­var­tis’ Tafin­lar (dabrafenib) and Mekin­ist (tram­e­tinib) com­bo has been ap­proved for an­oth­er in­di­ca­tion by the FDA — this time for treat­ment of low-grade glioma with a …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

COO / Head of Operations (Stealth Portfolio Company)‬ ‭

Autonomy Bio Inc.

San Francisco, CA 94107, USA

TRENDING NOW

Bio­haven stock sinks on three-month de­lay for neu­ro drug's FDA ap­proval de­ci­sion

Mer­ck KGaA will con­tin­ue to add a tar­iff sur­charge for US cus­tomers 

Hen­grui, one of Chi­na's lead­ing biotechs, an­tic­i­pates $1.2B in pro­posed Hong Kong list­ing

FDA gives Ab­b­Vie ac­cel­er­at­ed ap­proval for an­ti­body-drug con­ju­gate in lung can­cer

Sanofi touts $20B in­vest­ment in US over five years

RFK Jr. de­fends HHS staff cuts, re­or­ga­ni­za­tion plans in House, Sen­ate hear­ings

A service from the Financial Times